Protocol of the SOCFC project: a longitudinal cohort study of ovarian cancer patients, high-risk populations, and healthy controls to identify factors and biomarkers associated with disease diagnosis and prognosis.

IF 3.4 2区 医学 Q2 ONCOLOGY BMC Cancer Pub Date : 2025-02-26 DOI:10.1186/s12885-025-13652-9
Wenpei Shi, Yue Zhang, Shanshan Cheng, Yaqian Zhao, Na Li, Yi Li, Yingying Yang, Hui Ding, Zhen Li, Yu Wang
{"title":"Protocol of the SOCFC project: a longitudinal cohort study of ovarian cancer patients, high-risk populations, and healthy controls to identify factors and biomarkers associated with disease diagnosis and prognosis.","authors":"Wenpei Shi, Yue Zhang, Shanshan Cheng, Yaqian Zhao, Na Li, Yi Li, Yingying Yang, Hui Ding, Zhen Li, Yu Wang","doi":"10.1186/s12885-025-13652-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Ovarian cancer (OC) poses a significant threat to women's health due to its insidious onset, tendency to metastasize, and high recurrence rate. These characteristics significantly impede early diagnosis and effective interventions. The current lack of effective screening and prognostic tools necessitates urgent solutions. The Shanghai Ovarian Cancer and Family Care Project (SOCFCP) is an ongoing cohort study aiming to address these challenges by identifying factors and biomarkers associated with OC onset, treatment, and prognosis. The ultimate goal is to develop predictive models and assessments crucial for diagnosing, treating, and prognosing the disease.</p><p><strong>Methods: </strong>During the study period from 2023 to 2028, the SOCFCP aims to recruit over 2000 patients with ovarian lesions, 900 high-risk individuals, and 3000 healthy controls in Shanghai, China, with long-term follow-up. The study comprises three cohorts: (1) a bidirectional patients cohort, comprising those diagnosed with ovarian disease and treated at the department of gynecologic oncology at Shanghai first maternity and infant hospital since 2013; (2) a prospective high-risk cohort, consisting of family members of ovarian and/or breast cancer patients, or individuals with related gene mutations; and (3) a healthy control cohort, drawn from women undergoing health examination at hospitals or participating in community gynecologic cancer screenings. Participants will attend regular visits for questionnaire surveys, anthropometric measurements, and the collection of biological specimens, such as blood, fecal, and tissue samples. Collected data encompass baseline information, sociodemographic details, hospital admission records, and biological and clinical parameters, alongside treatment information. Primary outcomes for the patient cohort include mortality, tumor recurrence, major complications, and changes in health-related quality of life post-diagnosis. For the high-risk and healthy cohorts, ovary-related diseases will serve as the primary outcome. Various predictive models, such as multivariate logistic models, Cox regression, and linear mixed-effects regression models, will be employed to analyze various endpoints appropriately.</p><p><strong>Discussion: </strong>This extensive cohort study integrates a diverse range of information, including lifestyle factors, environmental influences, genetic characteristics, and clinical features, alongside an extensive collection of biological samples. The resources generated by this project will provide valuable foundations for a comprehensively understanding of the etiology, treatment, and prognosis of OC. The SOCFCP is poised to foster cutting-edge multidisciplinary research on OC, spanning both fundamental and clinical studies.</p><p><strong>Trial registration: </strong>NCT06118307 in ClinicalTrials.gov. Registration Date: November 7, 2023.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"355"},"PeriodicalIF":3.4000,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11863905/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12885-025-13652-9","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Ovarian cancer (OC) poses a significant threat to women's health due to its insidious onset, tendency to metastasize, and high recurrence rate. These characteristics significantly impede early diagnosis and effective interventions. The current lack of effective screening and prognostic tools necessitates urgent solutions. The Shanghai Ovarian Cancer and Family Care Project (SOCFCP) is an ongoing cohort study aiming to address these challenges by identifying factors and biomarkers associated with OC onset, treatment, and prognosis. The ultimate goal is to develop predictive models and assessments crucial for diagnosing, treating, and prognosing the disease.

Methods: During the study period from 2023 to 2028, the SOCFCP aims to recruit over 2000 patients with ovarian lesions, 900 high-risk individuals, and 3000 healthy controls in Shanghai, China, with long-term follow-up. The study comprises three cohorts: (1) a bidirectional patients cohort, comprising those diagnosed with ovarian disease and treated at the department of gynecologic oncology at Shanghai first maternity and infant hospital since 2013; (2) a prospective high-risk cohort, consisting of family members of ovarian and/or breast cancer patients, or individuals with related gene mutations; and (3) a healthy control cohort, drawn from women undergoing health examination at hospitals or participating in community gynecologic cancer screenings. Participants will attend regular visits for questionnaire surveys, anthropometric measurements, and the collection of biological specimens, such as blood, fecal, and tissue samples. Collected data encompass baseline information, sociodemographic details, hospital admission records, and biological and clinical parameters, alongside treatment information. Primary outcomes for the patient cohort include mortality, tumor recurrence, major complications, and changes in health-related quality of life post-diagnosis. For the high-risk and healthy cohorts, ovary-related diseases will serve as the primary outcome. Various predictive models, such as multivariate logistic models, Cox regression, and linear mixed-effects regression models, will be employed to analyze various endpoints appropriately.

Discussion: This extensive cohort study integrates a diverse range of information, including lifestyle factors, environmental influences, genetic characteristics, and clinical features, alongside an extensive collection of biological samples. The resources generated by this project will provide valuable foundations for a comprehensively understanding of the etiology, treatment, and prognosis of OC. The SOCFCP is poised to foster cutting-edge multidisciplinary research on OC, spanning both fundamental and clinical studies.

Trial registration: NCT06118307 in ClinicalTrials.gov. Registration Date: November 7, 2023.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
SOCFC项目方案:对卵巢癌患者、高危人群和健康对照者进行纵向队列研究,以确定与疾病诊断和预后相关的因素和生物标志物。
背景:卵巢癌(OC)发病隐匿、易转移、复发率高,对女性健康构成重大威胁。这些特征严重阻碍了早期诊断和有效干预。目前缺乏有效的筛查和预后工具,迫切需要解决这一问题。上海卵巢癌及家庭护理项目(SOCFCP)是一项正在进行的队列研究,旨在通过识别与卵巢癌发病、治疗和预后相关的因素和生物标志物来解决这些挑战。最终目标是建立对诊断、治疗和预后至关重要的预测模型和评估。方法:在2023 - 2028年的研究期间,SOCFCP计划在中国上海招募2000多名卵巢病变患者、900多名高危人群和3000名健康对照者,进行长期随访。本研究包括三个队列:(1)双向患者队列,包括2013年以来在上海市第一妇婴医院妇科肿瘤就诊的卵巢疾病患者;(2)前瞻性高风险队列,包括卵巢癌和/或乳腺癌患者的家庭成员,或有相关基因突变的个体;(3)健康对照队列,从在医院接受健康检查或参加社区妇科癌症筛查的妇女中抽取。参与者将定期参加问卷调查、人体测量和生物标本收集,如血液、粪便和组织样本。收集的数据包括基线信息、社会人口统计细节、住院记录、生物学和临床参数以及治疗信息。患者队列的主要结局包括死亡率、肿瘤复发、主要并发症和诊断后健康相关生活质量的变化。对于高风险和健康队列,卵巢相关疾病将作为主要结局。将使用各种预测模型,如多元逻辑模型,Cox回归和线性混合效应回归模型,以适当地分析各种端点。讨论:这项广泛的队列研究整合了多种信息,包括生活方式因素、环境影响、遗传特征和临床特征,以及广泛收集的生物样本。本项目所产生的资源将为全面了解卵巢癌的病因、治疗和预后提供有价值的基础。SOCFCP准备促进前沿的多学科研究,包括基础研究和临床研究。试验注册:NCT06118307, ClinicalTrials.gov。报名日期:2023年11月7日。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
BMC Cancer
BMC Cancer 医学-肿瘤学
CiteScore
6.00
自引率
2.60%
发文量
1204
审稿时长
6.8 months
期刊介绍: BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.
期刊最新文献
CALLY index provides improved prognostic stratification compared with other inflammation-based scores in glioblastoma treated with the stupp protocol. Diagnostic accuracy of an AI-based pathologic response assessment in locally advanced non-small cell lung cancer after neoadjuvant chemo-immunotherapy. Presenting the Brazilian physical activity during cancer treatment guidelines: adaptations and challenges in a low- and middle-income context. PROTECTOR / FIRE‑10: study protocol for a prospective, randomized, open-label, multicenter phase III trial to investigate the efficacy of preoperative systemic therapy in advanced colon cancer. Mammographic screening and time to breast cancer diagnosis among immigrants and long-term residents in Ontario.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1